Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives

Medicinal Chemistry

Volumn 9, Issue 1, 2013, Pages 91-99

  Kulkarni, Ravindra G ^a,d   Laufer, Stefan A ^b   Chandrashekhar, V M ^c   Garlapati, Achaiah ^d  

^a Shri Vithal Education and Research Institute s   (India)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Shri BVVSangha's Hanagal Shri Kumareshwar College of Pharmacy   (India)

^d KAKATIYA UNIVERSITY   (India)

Author keywords

Anti inflammatory activity; Benzimidazoles; P38 kinase inhibitors

Indexed keywords

2 (4 FLUOROPHENYL) 5 NITROBENZIMIDAZOLE; 2 (4 METHOXYPHENYL) 5 NITROBENZIMIDAZOLE; 2 (4' FLUOROPHENYL) 5 N (4'' METHOXYBENZOYL)AMINOBENZIMIDAZOLE; 2 (4' FLUOROPHENYL) 5 N (4'' NITROBENZOYL)AMINOBENZIMIDAZOLE; 2 (4' METHOXYPHENYL) 5 N (4'' NITROBENZOYL)AMINOBENZIMIDAZOLE; 2 (4' METHOXYPHENYL) 5 N BENZOYLAMINOBENZIMIDAZOLE; 2 (4'' FLUOROPHENYL) 5 N (4'' CHLOROBENZOYL)AMINOBENZIMIDAZOLE; 2 (4'' FLUOROPHENYL) 5 N BENZOYLAMINOBENZIMIDAZOLE; 2 PHENYL 5 N (4'' CHLOROBENZOYL)AMINOBENZIMIDAZOLE; 2 PHENYL 5 N (4'' NITROBENZOYL)AMINOBENZIMIDAZOLE; 5 AMINO 2 PHENYLBENZIMIDAZOLE; 5 N BENZOYLAMINO 2 PHENYL BENZIMIDAZOLE; ANTIINFLAMMATORY AGENT; BENZIMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84874079581     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340613804488440     Document Type: Article

References (45)

1. Brennan, F.; McInnes, I. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest., 2008, 118, 3537-45.
2. Bradley, J. TNF-mediated inflammatory disease. J. Pathol., 2008, 214, 149-60.
3. Boker, A.; Kimball, A. B.; Rolz-Cruz, G. Biologicals in the treatment of psoriasis. Curr. Opin. Invest. Drugs, 2007, 8, 939-46.
4. Tutrone, W.; Weinberg, J. Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept. Expert Rev. Dermatol., 2006, 1, 207-16.
5. Bruns, H.; Meinken, C.; Schauenberg, P.; Härter, G.; Kern, P.; Modlin, R.; Antoni, C.; Stenger, S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest., 2009, 119, 1167-77.
6. Kulkarni, R.; Achaiah, G.; Sastry, N. Novel targets for antiinflammatory and antiarthritic agents. Curr. Pharm. Des., 2006, 12, 2437-54.
7. Schindler, J.; Monahan, J.; Smith, W. p38 pathway kinases as antiinflammatory drug targets. J. Dent. Res., 2007, 86, 800-11.
8. Lee, J. C.; Laydon, J. T.; Mcdonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; Mcnulty, D.; Blumenthal, M. J.; Keys, J. R.; Vatter, S. W. L.; Strickler, J. E.; Mclaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, 739-46.
9. Ono, K.; Han, J. The p38 signal transduction pathway: activation and function. Cell Sign., 2000, 12, 1-13.
10. Zarubin, T.; Han, J. Activation and signalling of the p38 MAP kinase pathway. Cell Res., 2005, 15, 11-18.
11. Wagner, G.; Laufer, S. Small molecular anti-cytokine agents. Med. Res. Rev., 2006, 26, 1-62.
12. Dominguez, C.; Powers, D.; Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Disc. Dev., 2005, 8, 421-30.
13. Cirillo, P.; Pargellis, C.; Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med. Chem., 2002, 2, 1021-35.
14. ] Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R.; Cohen, P.; Gallagher, T. F,; Young, P. R.; Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homolog which is stimulated by cellular stresses and interleukin-1. FEBS Let., 1995, 364, 229-33.
15. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem., 2002, 45, 2994-3008.
16. Regan, J.; Capolino, A.; Cirillo, P.; Gilmore, T.; Graham, A.; Hickey, E.; Kroe, R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. SAR of the p38α MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl- 2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1- yl]urea (BIRB796). J. Med. Chem., 2003, 46, 4676-86.
17. Regan, J.; Pargellis, C.; Cirillo, P.; Gilmore, T.; Hickey, E.; Peet, G.; Proto, A.; Swinamer, A.; Moss, N. The kinetics of binding to p38 MAP kinase by analogues of BIRB796. Bioorg. Med. Chem. Let., 2003, 13, 3101-04.
18. Hong, S.; Chung, K.; You, H.; Choi, I.; Chae, M.; Han, J.; Jung, O.; Kang, S.; Ryu, C. Synthesis and biological evaluation of benzimidazole-4,7- diones that inhibit vascular smooth muscle cell proliferation. Bioorg. Med. Chem. Lett., 2004, 14, 3563-66.
19. White, A.; Curtin, N.; Eastman, B.; Golding, B.; Hostomsky, Z.; Kyle, S.; Li, J.; Maegley, M.; Skalitzky, D.; Webber, S.; Yu, X.; Griffin, R. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4- carboxamide PARP-1 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2433-37.
20. Kazimierczuk, Z.; Andrzejewska, M.; Kaustova, J.; Klimesova, V. Synthesis and anti-mycobacterial activity of 2-substituted halogenobenzimidazoles. Eur. J. Med. Chem., 2005, 40, 203-08.
21. Sondhi, S.; Singh, N.; Kumar, A.; Lozach, O.; Meijer, L. Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. Bioor. Med. Chem. Letts., 2006, 14, 3758-65
22. Guillaume D.; Bernard, P.; Armel, F.; Jacqueline, B. 5-imidazol-1- yl-1H-benzimidazole inhibitors of interleukin-1: a new pathway for the treatment of osteoarthritis. Actualite Chemique, 2000, 7-8, 48- 54.
23. Stavenger, R.; Cui, H.; Dowdell, S.; Franz, R.; Gaitanopoulos, D.; Goodman, K.; Hilfiker, M.; Ivy, R.; Leber, J.; Marino, J.; Oh, H.; Viet, A.; Xu, W.; Ye, G.; Zhang, D.; Zhao, Y.; Jolivette, L.; Head, M.; Semus, S.; Elkins, P.; Kirkpatrick, R.; Dul, E.; Khandekar, S.; Yi, T.; Jung, D.; Wright, L.; Smith, G.; Behm, D.; Doe, C.; Bentley, R.; Chen, Z.; Hu, E.; Lee, D. Discovery of aminofurazanaza benzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and anti hypertensive activity. J. Med. Chem., 2007, 50, 2-5.
24. Wittman, M. D.; Balasubramanian, B.; Stoffan, K.; Velaparthi, U.; Liu, P.; Krishnanathan, S.; Carboni, J.; Li, A.; Greer, A.; Attar, R.; Gottardis, M.; Chang, C.; Jacobson, B.; Sun, Y.; Hansel, S.; Zoeckler, M.; Vyas, D.M. Novel 1H-(benzimidazol-2-yl)-1Hpyridin- 2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg. Med. Chem. Lett., 2007, 17, 974-77.
25. Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P.; Sato, H.; Mori, I.; West, R.; Shibahara, M.; Toyoda, H.; Wang, L.; Nolte, R.; Veal, J.; Cheung, M. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J. Med. Chem., 2007, 50, 4453-70.
26. Snow R.J.; Abeywardane, A.; Campbell, S.; Lord, J.; Kashem, M.A.; Khine, H.H.; King, J.; Kowalski, J.A.; Pullen, S.S.; Roma, T.; Roth, G.P.; Sarko, C.R.; Wilson, N.S.; Winters, M.P.; Wolak, J.P.; Cywin, C.L. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3660-65.
27. Arienti, K.; Brunmark, A.; Axe, F.; McClure, K.; Lee, A.; Blevitt, J.; Neff, D.; Huang, L.; Crawford, S.; Pandit, C.; Karlsson, L.; Breitenbucher, J. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem., 2005, 48, 1873-85.
28. Ramurthy, S.; Subramanian, S.; Aikawa, M.; Amiri, P.; Costales, A.; Dove, J.; Fong, S.; Jansen, J.M.; Levine, B.; Ma, S.; McBride, C.M.; Michaelian, J.; Pick, T.; Poon, D.J.; Girish, S.; Shafer, C.M.; Stuart, D.; Sung, L.; Renhowe, P. A. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem., 2008, 51, 7049-52
29. de Dios, A.; Shih, C.; Lopez de, B.; Sanchez, C.; del Prado, M. M.; Cabrejas, L.; Pleite, S.; Blanco-Urgoiti J.; Lorite, M.; Nevill, C.; Bonjouklian, R.; York, J.; Vieth, M.; Wang, Y.; Magnus, N.; Campbell, R.; Anderson, B.; McCann, D.; Giera, D.; Lee, P.; Schultz, R.; Li, L.; Johnson, L.; Wolos, J. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J. Med. Chem., 2005, 48, 2270-73.
30. Mader, M.; de Dios, A.; Shih, C.; Bonjouklian, R.; Li, T.; White, W.; López de Uralde, B.; Sánchez-Martinez, C.; del Prado, M.; Jaramillo, C.; de Diego, E.; Martín Cabrejas, L. M.; Dominguez C.; Montero, C.; Shepherd, T.; Dally, R.; Toth, J. E.; Chatterjee, A.; Pleite, S.; Blanco-Urgoiti, J.; Perez, L.; Barberis, M.; Lorite, M. J.; Jambrina, E.; Nevill, C. R.; Lee, P. A.; Schultz, R. C.; Wolos, J. A.; Li, L. C.; Campbell, R. M.; Anderson, B. D. Imidazolyl benzimidazoles and imidazo [4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg. Med. Chem. Lett., 2008, 18, 179-83.
31. Hammach, A.; Barbosa, A.; Gaenzler, F.C.; Fadra, T.; Goldberg, D.; Hao, M.H.; Kroe, R.R.; Liu, P.; Qian, K.C.; Ralph, M.; Sarko, C.; Soleymanzadeh, F.; Moss, N. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett., 2006, 16, 6316-20
32. Bonjouklian, R.; De Diego, G.J.; De Dios, A.; Hamdouchi, C.H.; Li, T.; De Uralde, G.B.; Vieth, M.; York, J.S.; Dally, R.D.; Del Prado, C.M.F.; Jaramillo, A.C.; Martin-cabrejas, L.M.; Montero, S.C.; Pleite, S.S.; Sanchez-martinez, C.; Shepherd, T.A.; Wikel, J.H. US. 7,320,995 B2.
33. Sabat, M.; Vanrens, J.C.; Clark, M.P.; Brugel, T.A.; Maier, J.; Bookland, R.G.; Laufersweiler, M.J.; Laughlin, S.K.; Golebiowski, A.; De, B.; Hsieh, L.C.; Walter, R.L.; Mekel, M.J.; Janusz, M.J. The development of novel C-2, C-8 and N-9 trisubstituted purines as inhibitors of TNFα production. Bioorg. Med. Chem. Letts., 2006, 16, 4360-65
34. Ravindra, G.K. Design and synthesis of new hetercyclic compounds as anti-inflammatory agents. Ph.D. Thesis, Kakatiya University at Warangal, 2009, 1-60.
35. Göker, H.; Tunçbilek, M.; Süzen, S.; Kus, C.; Altanlar, N. Synthesis and antimicrobial activity of some new 2-phenyl-Nsubstituted carboxamido-1H-benzimidazole derivatives. Arch. Pharm. Med. Chem., 2001, 334, 148-52
36. Bellamy, F.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tet. Lett., 1984, 25, 839-42.
37. Gowda, D.; Mahesh, B.; Shankare, G. Zinc-Catalyzed Ammonium Formate Reductions: Reduction of Nitro Compounds. Ind. J. Chem. Sect. B, 2001, 40, 75-77.
38. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid phase assay. Anal. Biochem., 2005, 344, 135-37.
39. Ecobichon D. In The basis of toxicology testing; RC press: New York, 1997, 43-86.
40. Winter, C.; Risley, E.; Nuss, G. Carrageenan induced oedema hind paw of the rats as an assay for anti-inflammatory drugs. Proc. Soc. Bio. Med., 1962, 111, 544-47.
41. Diwan, P.; Karwande, I.; Margaret, I.; Sattur, P. Pharmacology and biochemical evaluation of Tridax procumbens on inflammation. Ind. J. Pharm., 1989, 21, 1-8.
42. Kumar, A.; Ilavarasan, R.; Jayachandran, T.; Deecaraman, M.; Kumar, R.; Aravindan, P.; Padmanabhan, N.; Krishan, M. Antiinflammatory activity of Syzygium cumini seed. Afr. J. Biotech., 2008, 7, 941-43.
43. Kulkarni R.G, Srivani P, Sastry G.N, Achaiah G. Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modelling study. J. Comput. Aided Mol. Des., 2007, 21, 155-166.
44. GOLD, version 2.2, Cambridge Crystallographic Data Centre: Cambridge, U. K
45. Tong, L.; Pav, S.; White, D.; Rogers, S.; Crane, K.; Cywin, C.; Brown, M.; Pargellis, C. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol., 1997, 4, 311-16.